CY1123035T1 - Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3 - Google Patents

Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3

Info

Publication number
CY1123035T1
CY1123035T1 CY20201100271T CY201100271T CY1123035T1 CY 1123035 T1 CY1123035 T1 CY 1123035T1 CY 20201100271 T CY20201100271 T CY 20201100271T CY 201100271 T CY201100271 T CY 201100271T CY 1123035 T1 CY1123035 T1 CY 1123035T1
Authority
CY
Cyprus
Prior art keywords
diphtheria toxin
interleukin
conjugates
methods
compositions based
Prior art date
Application number
CY20201100271T
Other languages
English (en)
Inventor
Arthur E. Frankel
Original Assignee
Scott & White Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Memorial Hospital filed Critical Scott & White Memorial Hospital
Publication of CY1123035T1 publication Critical patent/CY1123035T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Abstract

Η παρούσα εφεύρεση παρέχει μία φαρμακευτική σύνθεση που περιλαμβάνει ένα σύζευγμα ανθρώπινης ιντερλευκίνης (ΙL)-3-τοξίνης της διφθερίτιδας για χρήση σε μία μέθοδο θεραπείας ενός καρκίνου από πλασματοκυτταροειδή δενδριτικά κύτταρα σε έναν άνθρωπο, όπου η εν λόγω μέθοδος περιλαμβάνει τη χορήγηση του εν λόγω συζεύγματος IL-3-τοξίνης της διφθερίτιδας στον εν λόγω άνθρωπο.
CY20201100271T 2006-09-07 2020-03-23 Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3 CY1123035T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84347106P 2006-09-07 2006-09-07
US93277207P 2007-06-01 2007-06-01
PCT/US2007/019481 WO2008030539A2 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
EP07837840.3A EP2063907B1 (en) 2006-09-07 2007-09-07 Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

Publications (1)

Publication Number Publication Date
CY1123035T1 true CY1123035T1 (el) 2021-09-14

Family

ID=39157851

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101153T CY1119654T1 (el) 2006-09-07 2017-11-03 Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
CY20201100271T CY1123035T1 (el) 2006-09-07 2020-03-23 Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171101153T CY1119654T1 (el) 2006-09-07 2017-11-03 Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3

Country Status (17)

Country Link
US (7) US7763242B2 (el)
EP (3) EP3520806B1 (el)
JP (6) JP5550905B2 (el)
AU (1) AU2007293047B2 (el)
CA (5) CA2923381A1 (el)
CY (2) CY1119654T1 (el)
DK (2) DK2063907T3 (el)
ES (2) ES2781402T7 (el)
FR (1) FR21C1017I2 (el)
HU (2) HUE048356T2 (el)
LT (2) LT3207941T (el)
LU (1) LUC00206I2 (el)
NL (1) NL301103I2 (el)
PL (2) PL3207941T6 (el)
PT (1) PT3207941T (el)
SI (1) SI3207941T1 (el)
WO (1) WO2008030539A2 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
DK2063907T3 (da) * 2006-09-07 2017-11-13 Arthur E Frankel Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
WO2010027802A2 (en) 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
US20110171219A1 (en) * 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
NZ601760A (en) * 2010-02-17 2013-10-25 Csl Ltd Compositions and methods for targeting type 1 interferon producing cells
CA2805412C (en) 2010-06-17 2021-04-27 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
EP2648748A1 (en) 2010-12-08 2013-10-16 Stem Centrx, Inc. Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2013006838A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6401060B2 (ja) 2012-02-24 2018-10-03 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｓｅｚ６抗体及び使用方法
DK2817338T3 (en) 2012-02-24 2017-10-23 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
MX2015010682A (es) 2013-02-22 2016-05-31 Stemcentrx Inc Nuevos conjugados de anticuerpos y usos de los mismos.
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
DK3052102T3 (da) 2013-10-04 2020-03-09 Aptose Biosciences Inc Sammensætninger til behandling af cancere
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
CA2932476A1 (en) 2013-12-12 2015-06-18 Stemcentrx, Inc. Novel anti-dpep3 antibodies and methods of use
JP2017514143A (ja) 2014-02-21 2017-06-01 アッヴィ・ステムセントルクス・エル・エル・シー メラノーマに使用するための抗ｄｌｌ３抗体および薬物コンジュゲート
LT3137114T (lt) 2014-04-30 2021-03-25 Pfizer Inc. Anti-ptk7 antikūnų ir vaistų konjugatai
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3454864A4 (en) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC NOVEL ANTI-BMPR1B ANTIBODIES AND METHOD OF USING
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
KR20200096914A (ko) 2017-10-30 2020-08-14 압토스 바이오사이언시스 인코포레이티드 암 치료용 아릴 이미다졸
US20210361744A1 (en) * 2018-04-27 2021-11-25 Stemline Therapeutics, Inc. Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3)
US20210148923A1 (en) * 2018-05-30 2021-05-20 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
BR112021007945A2 (pt) * 2018-10-31 2021-08-03 Stemline Therapeutics, Inc. método de terapia de combinação para tratar neoplasmas mieloproliferativos com um conjugado de toxina de difteria-interleucina-3 humana em combinação com outros agentes
WO2020112642A1 (en) 2018-11-30 2020-06-04 Stemline Therapeutics, Inc. Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
US20220411880A1 (en) * 2019-11-21 2022-12-29 Inserm (Institut National De La Santéet De La Recherche Médicale) Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml)
JP2023553106A (ja) 2020-12-10 2023-12-20 ステムライン セラピューティクス，インコーポレーテッド 改善された凍結乾燥製剤

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
JP2534222B2 (ja) 1982-05-12 1996-09-11 プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ 混成タンパク質生産用融合遺伝子
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
DE69132581T3 (de) 1990-03-02 2008-07-17 Boston Medical Center Corp., Boston Verbesserte chimäre toxine
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4140121C2 (de) 1991-12-05 1994-06-30 Manfred Mueller Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
WO1996038571A2 (en) * 1995-05-31 1996-12-05 Regents Of The University Of Minnesota Recombinant polypeptide cytotoxins for cancer treatment
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5843633A (en) 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU779803B2 (en) 1999-12-03 2005-02-10 Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland, The Dendritic cell-specific antibodies
AU5003001A (en) 2000-03-06 2001-09-17 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
MXPA03007878A (es) 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
AU2014201901B2 (en) 2006-09-07 2016-05-05 Scott & White Healthcare Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
DK2063907T3 (da) * 2006-09-07 2017-11-13 Arthur E Frankel Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2820030A4 (en) 2012-02-29 2015-04-15 Ambrx Inc INTERLEUKIN-3-POLYPEPTIDE CONJUGATES AND ITS USES

Also Published As

Publication number Publication date
CA3053981A1 (en) 2008-03-13
US9181317B2 (en) 2015-11-10
EP3520806A1 (en) 2019-08-07
WO2008030539A3 (en) 2009-04-09
JP2016155830A (ja) 2016-09-01
JP5550905B2 (ja) 2014-07-16
CA2923381A1 (en) 2008-03-13
US9631006B2 (en) 2017-04-25
US10259853B2 (en) 2019-04-16
CA2698595A1 (en) 2008-03-13
EP3207941A1 (en) 2017-08-23
DK2063907T3 (da) 2017-11-13
EP2063907A2 (en) 2009-06-03
CA3153438A1 (en) 2008-03-13
JP6654660B2 (ja) 2020-02-26
US20090232767A1 (en) 2009-09-17
WO2008030539A2 (en) 2008-03-13
US20130315860A1 (en) 2013-11-28
DK3207941T3 (da) 2020-03-30
NL301103I2 (nl) 2021-08-02
LT3207941T (lt) 2020-04-10
EP3207941B3 (en) 2020-08-19
JP5902223B2 (ja) 2016-04-13
SI3207941T1 (sl) 2020-08-31
ES2781402T3 (es) 2020-09-01
CA3007075A1 (en) 2008-03-13
JP2014144967A (ja) 2014-08-14
LUC00206I2 (el) 2022-10-07
EP2063907A4 (en) 2011-08-31
ES2781402T7 (es) 2021-06-09
JP2010502712A (ja) 2010-01-28
HUS2100013I1 (hu) 2021-05-28
US20080138313A1 (en) 2008-06-12
EP3520806B1 (en) 2024-03-20
FR21C1017I1 (el) 2021-07-02
CA2698595C (en) 2016-07-26
US11130792B2 (en) 2021-09-28
US20220235108A1 (en) 2022-07-28
US20160024167A1 (en) 2016-01-28
JP2022065089A (ja) 2022-04-26
US8470307B2 (en) 2013-06-25
CA3007075C (en) 2019-10-15
PT3207941T (pt) 2020-04-02
US20180022788A1 (en) 2018-01-25
HUE048356T2 (hu) 2020-07-28
CA3153438C (en) 2024-03-12
CA3053981C (en) 2022-07-12
JP2018135378A (ja) 2018-08-30
AU2007293047A1 (en) 2008-03-13
JP6336500B2 (ja) 2018-06-06
ES2646545T3 (es) 2017-12-14
FR21C1017I2 (fr) 2022-04-22
LTPA2021507I1 (el) 2021-06-10
JP2020079260A (ja) 2020-05-28
US7763242B2 (en) 2010-07-27
LTC3207941I2 (el) 2022-10-10
EP2063907B1 (en) 2017-08-09
NL301103I1 (nl) 2021-06-17
AU2007293047B2 (en) 2014-01-09
PL3207941T6 (pl) 2020-11-16
PL2063907T3 (pl) 2018-06-29
PL3207941T3 (pl) 2020-07-27
CY1119654T1 (el) 2019-07-10
US20190169251A1 (en) 2019-06-06
DK3207941T6 (da) 2020-11-09
EP3207941B1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
CY1123035T1 (el) Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
CY1122270T1 (el) Αντι-παραγοντα xi μονοκλωνικα αντισωματα και μεθοδοι χρησης αυτων
CY1117840T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
CY1114904T1 (el) Prlr-ειδικο αντισωμα και χρησεις αυτου
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
EP3838298A3 (en) Psma binding ligand-linker conjugates and methods for using
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
CY1109996T1 (el) Ανοσογονικη συνθεση
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
EA201100268A1 (ru) Вакцина
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
AR053338A1 (es) Terapia antiproliferativa combinada usando ciertos agentes quimioterapeuticos basados en platino y taxanos
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη